In yesterday’s Wall Street session, Taysha Gene Therapies Inc. (NASDAQ:TSHA) shares traded at $2.34, up 4.00% from the previous session.
As of this writing, 15 analysts cover Taysha Gene Therapies Inc. (NASDAQ:TSHA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $24.00 and a low of $3.00, we find $16.00. Given the previous closing price of $2.25, this indicates a potential upside of 611.11 percent. TSHA stock price is now 15.33% away from the 50-day moving average and -40.59% away from the 200-day moving average. The market capitalization of the company currently stands at $149.25M.
There are 1 analysts who have given it a hold rating, whereas 13 have given it a buy rating. Brokers who have rated the stock have averaged $16.64 as their price target over the next twelve months.
With the price target reduced from $16 to $3, Goldman Downgraded its rating from Buy to Neutral for Taysha Gene Therapies Inc. (NASDAQ: TSHA). On March 09, 2022, Robert W. Baird recently initiated its ‘Outperform’ rating on the stock quoting a target price of $26, while ‘Wells Fargo’ rates the stock as ‘Overweight’.
In other news, Manning Paul B, Director bought 1,500,000 shares of the company’s stock on Oct 31. The stock was bought for $3,000,000 at an average price of $2.00. Upon completion of the transaction, the Director now directly owns 1,642,202 shares in the company, valued at $3.84 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 23, Chief Financial Officer Alam Kamran sold 3,325 shares of the business’s stock. A total of $11,538 was realized by selling the stock at an average price of $3.47. This leaves the insider owning 266,121 shares of the company worth $0.62 million. Insiders disposed of 95,000 shares of company stock worth roughly $0.22 million over the past 1 year. A total of 3.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TSHA stock. A new stake in Taysha Gene Therapies Inc. shares was purchased by PARAMETRIC PORTFOLIO ASSOCIATES LLC during the first quarter worth $44,000. BORDEAUX WEALTH ADVISORS LLC invested $23,000 in shares of TSHA during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Taysha Gene Therapies Inc. valued at approximately $8,000. CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. acquired a new stake in TSHA for approximately $1,000. SIMPLEX TRADING, LLC purchased a new stake in TSHA valued at around $1,000 in the second quarter. In total, there are 96 active investors with 22.20% ownership of the company’s stock.
Wednesday morning saw Taysha Gene Therapies Inc. (NASDAQ: TSHA) opened at $2.2400. During the past 12 months, Taysha Gene Therapies Inc. has had a low of $1.35 and a high of $15.34. As of last week, the company has a debt-to-equity ratio of 3.41, a current ratio of 1.30, and a quick ratio of 1.30. The fifty day moving average price for TSHA is $2.0290 and a two-hundred day moving average price translates $3.9389 for the stock.
The latest earnings results from Taysha Gene Therapies Inc. (NASDAQ: TSHA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.84, beating analysts’ expectations of -$1 by 0.16. This compares to -$1.35 EPS in the same period last year. The company reported revenue of $25.07 million for the quarter, compared to $50.68 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -50.53 percent.
Taysha Gene Therapies Inc.(TSHA) Company Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.